title: A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.
abstract: BACKGROUND
  Individuals with schizophrenia smoke at higher rates (58%-88%) than the general population (approximately 22%), and have difficulty quitting. We determined whether the combination of sustained-release (SR) bupropion (BUP) with the transdermal nicotine patch (TNP) was well-tolerated and superior to placebo (PLO)+TNP for smoking cessation in schizophrenia.
  
  
  METHODS
  A 10-week, double-blind, placebo-controlled trial of BUP (300 mg/day) in combination with TNP (21 mg/24h) for 58 outpatient smokers with schizophrenia was conducted. Primary outcome measures were continuous smoking abstinence in the last 4 weeks of the trial (Days 43-70) and 7-day point prevalence abstinence at 6 months post-target quit date (TQD) (week 26).
  
  
  RESULTS
  Smokers assigned to the BUP+TNP group (n = 29) were more likely to achieve continuous smoking abstinence (8/29, 27.6%) than the PLO+TNP group (n = 29, 1/29, 3.4%) [Fisher's Exact Test, p < .05]; at 6-months post-TQD, 4/29 (13.8%) versus 0/29 (0.0%) achieved 7-day point prevalence smoking abstinence (p = .11). Neither bupropion SR nor smoking abstinence significantly altered the positive or negative symptoms of schizophrenia. The combination was well-tolerated in smokers with schizophrenia.
  
  
  CONCLUSIONS
  Combination therapy with bupropion SR+TNP versus placebo+TNP is well-tolerated and significantly improved short-term smoking abstinence in smokers with schizophrenia.
authors: Centre for Addiction and Mental Health, Faculty of Medicine, University of Toronto, Ontario, Canada. Tony_George@camh.net
authors: Tony P
authors: TP
authors: George
authors: Jennifer C
authors: JC
authors: Vessicchio
authors: Kristi A
authors: KA
authors: Sacco
authors: Andrea H
authors: AH
authors: Weinberger
authors: Melissa M
authors: MM
authors: Dudas
authors: Taryn M
authors: TM
authors: Allen
authors: Cerissa L
authors: CL
authors: Creeden
authors: Marc N
authors: MN
authors: Potenza
authors: Alan
authors: A
authors: Feingold
authors: Peter I
authors: PI
authors: Jatlow
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D012559:Schizophrenia / Q000150:complications; D012565:Schizophrenic Psychology; D016540:Smoking Cessation / Q000379:methods*; D013375:Substance Withdrawal Syndrome / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D013997:Time Factors
chemical_list: D018687:Antidepressive Agents, Second-Generation; D018722:Nicotinic Agonists; D016642:Bupropion; D009538:Nicotine